InterventionsHuman trial70 participants48 weeksRandomised trialDouble-blindPlacebo-controlledRegistered NCT06363851Declared ties to: Hygieia Pharmaceuticals, Eli Lilly and Company, Novartis and 2 more

Safety and lipoprotein(a)-lowering effects of Kylo-11, a non-canonical, long-duration small interfering RNA targeting lipoprotein(a): a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial

Lancet

The paper

Ashish Sarraju, Xiaolin Du, Luping Zhou,

Luke Joseph Laffin, Kathy Wolski, Yumei Gu, Ziyang Liu, Qinsheng Zhang, Kunyuan Cui, Xiaolan Yong,

Steven E. Nissen

Cleveland Clinic

Lancet · 28 Aug 2026

doi.org/10.1016/s0140-6736(26)01484-4 PubMed 42664979

Cumulative non-HDL cholesterol is linked to CVD risk
Journal of Diabetes and Metabolic Disorders · 4 Oct 2026
Estimated sdLDL-C predicts cardiovascular risk in Japanese adults
Journal of Clinical Lipidology · 4 Oct 2026
Martin-Hopkins LDL equation best predicts cardiovascular risk
Circulation Population Health and Outcomes · 4 Oct 2026
Mild caloric restriction accelerates atherosclerosis in mice
JCI Insight · 4 Oct 2026

Safety and lipoprotein(a)-lowering effects of Kylo-11, a non-canonical, long-duration small interfering RNA targeting lipoprotein(a): a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial

The paper

More on Lipid and ceramide metabolism